Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11025207 | 0.85 | CYP1A2 (0.44) | ALDH1A1LMNAPPARDTSHRSMN1; SMN2 | |
| SCHEMBL27939729 | 0.78 | TSHR (0.46) | ALDH1A1LMNAHSD17B10PPARDTSHR | |
| SCHEMBL10409275 | 0.78 | ALDH1A1 (0.47) | ALDH1A1LMNAHSD17B10PPARDTSHR | |
| SCHEMBL28231972 | 0.77 | PPARD (0.40) | ALDH1A1LMNAHSD17B10PPARDTSHR | |
| SCHEMBL16490170 | 0.75 | ALDH1A1 (0.50) | ALDH1A1LMNAHSD17B10PPARDTSHR | |
| SCHEMBL11021469 | 0.75 | CYP1A2 (0.50) | ALDH1A1HSD17B10TSHRSMN1; SMN2POLB | |
| SCHEMBL9945634 | 0.74 | PPARD (0.40) | ALDH1A1HSD17B10PPARDTSHRALOX15 | |
| SCHEMBL15635559 | 0.72 | ALDH1A1 (0.48) | ALDH1A1LMNAHSD17B10TSHRSMN1; SMN2 | |
| SCHEMBL17084061 | 0.72 | ALDH1A1 (0.48) | ALDH1A1LMNAHSD17B10TSHRSMN1; SMN2 | |
| SCHEMBL11022451 | 0.71 | FAAH (0.40) | ALDH1A1LMNAHSD17B10PPARDTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8901072-B2 | Glycopeptide and lipoglycopeptide antibiotics with improved solubility | THE MEDICINES COMPANY (US) | 2014-12-02 | — | — | US | disclosed |
| US-20120149632-A1 | GLYCOPEPTIDE AND LIPOGLYCOPEPTIDE ANTIBIOTICS WITH IMPROVED SOLUBILITY | THE MEDICINES COMPANY (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149632-A1 | GLYCOPEPTIDE AND LIPOGLYCOPEPTIDE ANTIBIOTICS WITH IMPROVED SOLUBILITY | NGLY1, LGALS3BP, GYPA | ALDH1A1 4197/4885LMNA 1400/4885HSD17B10 2565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.